This is a correction notice for a research study about psilocybin therapy used to treat depression in healthcare workers during the COVID-19 pandemic. The original article had several incorrect author affiliations that have now been corrected to properly list their departments at the University of Washington School of Medicine.
This study surveyed music festival and concert attendees in Colorado about their experiences using cannabis and psychedelics together. Researchers found that most people reported cannabis made their psychedelic experience better by reducing anxiety, enhancing mood, or intensifying effects. Only a small percentage experienced negative effects like increased anxiety or confusion. The study suggests cannabis may help people manage difficult psychedelic trips, though more research is needed to understand how different types and amounts of cannabis affect outcomes.
This paper reviews scientific research on psychedelic drugs like LSD and psilocybin that are being studied for treating depression and PTSD. While some research claims these drugs are beneficial, many studies have serious flaws including hiding negative side effects and being influenced by money from pharmaceutical companies. The author concludes that we need much better research before these drugs can be safely approved for medical use.
Researchers have translated an important measurement tool called the Challenging Experience Questionnaire into Japanese. This tool helps doctors and researchers measure difficult feelings like fear and anxiety that people sometimes experience when taking psilocybin mushrooms as part of therapy. Having this questionnaire available in Japanese is important because it allows Japanese patients and researchers to participate in psychedelic research and understand these experiences better.
This Polish study surveyed nearly 2,500 recreational drug users about their substance use patterns and mental health. The survey found that marijuana is the most commonly used illicit drug, but worryingly, most users don’t test what they’re taking or measure doses carefully. The study also revealed increasing use of mephedrone and other stimulants that are sending more people to hospitals, while interest in psychedelics is declining. Importantly, more people are now seeing psychiatrists and being honest about their drug use.
This study examines how antidepressant medications (like SSRIs) affect the experience of classic psychedelics such as psilocybin and LSD. Researchers found that people taking these antidepressants experienced less intense emotional and mystical effects from psychedelics, but surprisingly, both groups showed similar improvements in mood and well-being several weeks later. This raises important questions about whether patients need to stop their antidepressants before using psychedelics therapeutically.
This survey studied how autistic adults feel about using psychedelics like psilocybin mushrooms for mental health. Nearly 70% of participants had tried psychedelics before and most found them helpful for anxiety and depression. Many participants were interested in trying them or participating in research, though legal and practical barriers stood in the way. The study suggests that psychedelics could be a promising treatment option for autistic people with mental health challenges.
As psychedelic drugs show promise in treating serious mental health conditions like depression and PTSD, there is growing need to train therapists to safely administer these novel treatments. Switzerland’s leading medical association has developed a comprehensive three-year training program that combines classroom learning with hands-on practice to prepare doctors and psychologists. The program faces overwhelming demand, with far more people wanting to train than available spots, highlighting the urgent need for more specialized education programs as these treatments potentially become mainstream medications.
This case report describes a rare complication where ectopic splenic tissue (splenosis) that had grown in the abdomen following a previous spleen removal suddenly ruptured and caused severe internal bleeding. The 35-year-old patient developed acute abdominal pain and underwent emergency surgery to remove the bleeding tissue and stop the hemorrhage. The surgery was successful and the patient recovered well, highlighting the importance of considering splenosis in the differential diagnosis of unexplained abdominal bleeding in patients with prior spleen removal.
This research examined how taking very small doses of psychedelic substances like psilocybin mushrooms or LSD affects mental health and wellbeing. The study found that people who practice microdosing reported lower levels of depression, anxiety and stress compared to those who don’t microdose. Most participants used these substances to enhance mindfulness, improve mood, and boost creativity rather than to get high. Impacts on everyday life: • Provides evidence that microdosing may help manage common mental health issues like anxiety and depression • Suggests microdosing could be an alternative to traditional medications for some people • Shows potential for improving general wellbeing and cognitive performance in healthy individuals • Indicates microdosing may help reduce problematic alcohol and tobacco use • Highlights the importance of further research into safe and effective dosing practices